A mutation in the ubiquilin 2 gene (UBQLN2) was recently identified as a cause of X-linked amyotrophic lateral sclerosis (ALS)/ frontotemporal dementia (FTD) and a major component of the inclusion bodies commonly found with a wide variety of ALS. ALS-linked mutations in UBQLN2 are clustered in a unique proline-X-X repeat region, reportedly leading to impairment of the ubiquitin proteasome system. However, the molecular properties of mutant UBQLN2 remain unclear. To gain insight into the pathogenesis of UBQLN2-linked ALS/FTD, we examined the biochemical and cellular characteristics of mutant UBQLN2 in vitro. UBQLN2 localized in Rab11-positive endosomal vesicles formed by the ALS-linked molecule optineurin (OPTN). These vesicles were ubiquitin-and p62-immunopositive and also co-localized with an initiator of the autophagic process, ULK1, after amino acid starvation. An ALS-linked mutation (E478G) in OPTN abolished vesicle formation. ALS-linked mutations in UBQLN2 additively enhanced UBQLN2 aggregation and formation of inclusion bodies, resulting in mislocation from OPTN vesicles. UBQLN2 was found to be a potent regulator of the levels of the FTD-linked secretory factor progranulin, possibly via the endosomal system, and ALS-linked mutations disturbed these functional consequences. This study demonstrates that ALSlinked mutations in both OPTN and UBQLN2 interfere with the constitution of specific endosomal vesicles, suggesting that the vesicles are involved in protein homeostasis and that these proteins function in common pathological processes. These data suggest a novel disease spectrum and provide new pathological insights into OPTN and UBQLN2, enhancing our understanding of the molecular basis of ALS/FTD.
Introduction
Amyotrophic lateral sclerosis (ALS) is a fatal disorder caused by motor-neuron degeneration in the brain and spinal cord. Advanced genetic approaches have led to the rapid and successive identification of causative genes linked to ALS, furthering our understanding of the pathogenesis of this disease. Furthermore, evidence indicates that ALS and frontotemporal dementia (FTD) constitute a disease spectrum that shares a common molecular basis. Recently, Deng et al. identified mutations in the ubiquilin 2 gene (UBQLN2) that cause dominantly inherited, chromosome-X-linked ALS/FTD (1) . To date, five point mutations in the unique proline-X-X (PXX) repeat region of UBQLN2 (P497H, P497S, P506T, P509S and P525S) have been identified as being associated with familial ALS (1) . Pathological observations also revealed that UBQLN2 is a critical component in the skein-like inclusions of not just ALS with the UBQLN2 mutation but also a wide variety of ALS forms, indicating that UBQLN2 is a critical molecule in the pathogenesis of ALS (1) .
UBQLN is a multi-domain member of the UBL-UBA family of proteins (2) , which contain ubiquitin-like (UBL) and ubiquitin-associated (UBA) domains and are involved in the ubiquitin-proteasome system (UPS), the endoplasmic reticulum-associated protein degradation (ERAD) pathway and autophagy (3) (4) (5) (6) . Furthermore, UBQLN also contains two co-chaperone-like regions known as heat shock chaperonin-binding motifs [Stress-inducible protein-1 (STI-1)], which have also been shown to stabilize a number of proteasome substrates (5, (7) (8) (9) . Limited biochemical evidence has demonstrated the mechanisms underlying the pathogenesis of UBQLN2-linked ALS. A study using an UPS reporter substrate (UbG76V-GFP) indicated that the P497H mutation in UBQLN2 leads to ubiquitin-mediated impairment of proteasomal degradation. However, because UBQLN2 is a multifunctional protein and may be involved in multiple pathways of neurodegeneration, further study is necessary if we are to understand the molecular basis of this disease.
Here, we investigated the cellular and biochemical characteristics of UBQLN2 mutants as well as their interaction with other ALS/FTD-linked molecules. Our results revealed that mutations in UBQLN2 additively enhance aggregation and formation of cytoplasmic inclusions. We also demonstrated that UBQLN2 is localized in vesicles formed by another ALS-linked molecule, optineurin (OPTN). These vesicles are identical to Rab11-and ULK1-positive recycling endosomes associated with autophagosomes (10) . Furthermore, overexpression of UBQLN2 regulates the levels of FTD-linked molecules, progranulin, whereas mutant UBQLN2 disturbs these functions. Our findings reveal novel biochemical properties of UBQLN2 and OPTN and provide important insights that will enhance our understanding of the molecular basis of UBQLN2-linked ALS/FTD.
Results

Characterization of mutant UBQLN2 expression in cultured cells
In order to investigate the biochemical properties of mutant UBQLN2 in vitro, we first transiently overexpressed cDNAs encoding wild-type and ALS-linked UBQLN2 mutants [P497H, a double mutation (P497H + P525S, IIma; P506S + P509S, IImb), a triple mutation (P497H + P506T + P509S, IIIm) and a quadruple mutation (P497H + P506T + P509S + P525S, IVm)] with C-and N-terminal 6X myc tags in Neuro 2A (N2a) cells and analyzed their expression by immunoblotting with anti-myc antibodies. As shown in Figure 1A , all transiently transfected cells expressed a full-length (∼76 kDa) band and at least three major truncated bands between ∼35 and ∼48 kDa. Notably, cells expressing mutant UBQLN2 also showed a high-molecular-weight complex that increased in size with the number of mutations, indicating that mutations affect protein folding and/or structural conformation.
Next, a well-established filter retardation assay was used to evaluate aggregation of the UBQLN2 mutants (11) . The level of aggregated UBQLN2 protein, which is retained on the cellulose acetate membrane, was determined using densitometry, and the data were normalized to that of unaggregated full-length UBQLN2 (∼76 kDa), which was determined by western blotting. As shown in Figure 1B , the level of aggregated UBQLN2 for each of the mutants was significantly higher than that for wild-type UBQLN2, even for the single mutant (P497H), and the number of mutations had an additive effect on UBQLN2 aggregation.
Deng et al. reported that transfection with both wild-type and P497H mutant UBQLN2 results in the formation of cytoplasmic inclusion bodies (IBs) in N2a cells (1) . To explore this in more detail, we examined the subcellular localization of wild-type and mutant UBQLN2 in various transfected cell lines ( primary cortical neuron, N2a, NSC34, HeLa, COS and 293T) using several subcellular and pathological markers ( Fig. 2 ; Supplementary Material, Fig. S1A and B) . Immunofluorescent staining of cells expressing wild-type UBQLN2 showed that few cells formed cytoplasmic inclusions and that wild-type UBQLN2 localized primarily in the cytoplasm ( Fig. 2A and B) . By contrast, many cells expressing IIIm and IVm formed inclusions. Of ∼300 cells transfected in 3 independent experiments, IBs were detected in ∼1-2% of wild-type-, P497H-, IIma-and IImb-expressing cells (mean ± standard deviation; wild type, 1.19 ± 0.17%; P497H, 1.08 ± 0.23%; IIma, 1.66 ± 1.06%; IImb, 2.37 ± 0.78%). IB formation dramatically increased in cells expressing IIIm and IVm [IIIm, 11.94 ± 4.38% (P < 0.0001 versus wild-type); IVm, 11.81 ± 2.73% (P < 0.0001 versus wild-type)] (Fig. 2B) . These IBs were also detected in NSC34 neuronal cells and primary cortical neurons expressing IVm but were rarely observed in non-neuronal HeLa, COS or 293T cells, suggesting that IB formation occurs predominantly in neuronal cells (Supplementary Material, Fig. S1 ).
Because the unique PXX repeat region of UBQLN2 (1) (in which ALS-linked mutations are clustered) is thought to be critical for ALS pathogenesis, we generated a PXX deletion (ΔPXX) construct and assessed IB formation and aggregation. As shown in Figure 1A and B and Figure 2 , the high-molecular-weight complex and IBs were absent in the ΔPXX construct (% of cells with IBs: 1.15 ± 0.39%), indicating that ALS-linked mutations, but not mutations that cause loss of function of the PXX region, predominantly affect UBQLN2 assembly.
Characterization of IBs formed by mutant UBQLN2-expressing cells
Many mutant proteins associated with neurodegenerative diseases, such as huntingtin and SOD1, form ubiquitinated aggregates termed aggresomes (12, 13) , which have been wellcharacterized biochemically (12, (14) (15) (16) (17) (18) (19) (20) . A characteristic feature of aggresomes is that they form at the microtubule-organizing center (MTOC). This is consistent with the finding that misfolded proteins are commonly transported along microtubules and then assembled in and around the MTOC (12, (15) (16) (17) 20) . Another characteristic of aggresomes is deposition of intermediate filaments such as vimentin, which often forms a cage-like structure around inclusions (13) . To determine whether mutant UBQLN2-IBs and aggresomes are similar, we compared the distribution of mutant UBQLN2-IBs with that of pericentrin (an MTOC marker) and vimentin. As shown in Figure 3A and B, mutant UBQLN2-IBs were not localized within close proximity of the MTOC, and the distribution of vimentin also appeared to be unchanged around mutant UBQLN2-IBs. To directly compare the formation of mutant UBQLN2-IBs with that of aggresomes, we co-transfected cells with both IVm and truncated N-terminal huntingtin (tNhtt)-polyglutamine (60Q), which is from well-examined aggresomes. As shown in Figure 3C , IVm did not co-localize to the tNhtt-60Q-aggresomes but instead formed independent inclusions. From these results, we concluded that mutant UBQLN2-IBs are formed via a different mechanism than are aggresomes.
The protein degradation system mediators ubiquitin and p62 can be used as hallmark pathological markers of IB formation through specific labeling. To clarify whether cellular UBQLN2-IBs are associated with the protein degradation system, we stained IBs with anti-ubiquitin and anti-p62 antibodies. As shown in Figure 3D and E, UBQLN2-IBs were positive for both ubiquitin and p62, indicating that UBQLN2-IBs in cultured cells recapitulate inclusions in ALS/FTD brain tissue. Furthermore, the formation of mutant UBQLN2-IBs was dramatically increased in ATG5 (-/-) MEFs, which are defective in autophagy (Fig. 3F) . Therefore, these findings indicate that these IBs are regulated by the autophagic system.
We next sought to determine what region(s) of UBQLN2 are required for assembly with IBs. A series of mutant IVm constructs were prepared in N2a cells, and the formation of IBs was assessed (Supplementary Material, Fig. S2 ). The cells were transiently transfected with constructs in which the UBL and UBA domains and STI1 motif were deleted (ΔUBL, ΔUBA and ΔSTI1, respectively). Confocal microscopy analysis showed that ΔUBL and ΔSTI1 impeded IB formation (Supplementary Material, Fig. S2B and C), indicating that both UBL and STI1 mediate the assembly of mutant UBQLN2-IBs.
UBQLN2 co-localizes with OPTN vesicles
To clarify whether UBQLN2 interacts with other critical molecules associated with ALS, we compared cells expressing the ALS-linked G85R mutant SOD1, P525L mutant FUS or wild-type UBQLN2. As shown in Supplementary Material, Figure S3A A recent study revealed that mutations in the gene for the autophagy receptor OPTN also cause familial ALS (23) . It was also reported that overexpressed wild-type OPTN forms cytoplasmic vesicles. The glaucoma-linked mutant (E50K) often shapes large vesicles, whereas the ALS-linked mutant (E478G) protein does not (24) . Because both OPTN and UBQLN2 function in the protein degradation system, we then examined whether there is an association between UBQLN2-and OPTN-containing vesicles. As shown in Figure 4 and Supplementary Material, Figure S4 , endogenous UBQLN2 and overexpressed wild-type UBQLN2 localized in wild-type and E50K mutant OPTN vesicles in both N2a and HeLa cells. Examination of a series of deletion mutants revealed that the UBL, STI1 and UBA domains, but not the PXX domain, are critical for localization to OPTN vesicles (Supplementary Material, Fig. S5 ), thus providing compelling evidence that the ALS-linked molecules, OPTN and UBQLN2, both localize to the same cellular compartment.
Characterization of OPTN+/UBQLN2+ vesicles
Nagabhushana et al. reported that OPTN vesicles function in endosome recycling and regulation of endocytic trafficking (24) . Using several endosomal markers, we confirmed this finding in cells co-expressing wide-type UBQLN2 and OPTN. Co-overexpression of both proteins with GFP-fused markers of the early endosome (mRFP-Rab5), late endosome (GFP-Rab7) and recycling endosome (GFP-Rab11) revealed that OPTN vesicles co-localize with GFP-Rab11 The bar graph shows the level of aggregated UBQLN2 normalized to the unaggregated UBQLN2 (mean ± SD). Symbols (# and ##) indicate a significant difference versus wild-type (P < 0.05 and P < 0.01, respectively).
(Supplementary Material, Fig. S6 ), but only partially with Rab5 and Rab7. The OPTN+/UBQLN2+ vesicles showed clear Rab11 immunoreactivity on staining with anti-Rab11 antibody (Supplementary Material, Fig. S7A and B) .
To clarify the function of OPTN+/UBQLN2+ vesicles, we examined endosomal trafficking in transfected HeLa cells expressing OPTN and UBQLN2. Transferrin and the transferrin receptor are typically used to study endocytosis and recycling. Upon binding iron, transferrin is endocytosed through the transferrin receptor and delivered to the early endosome, after which most of the transferrin and transferrin receptor molecules are recycled through the recycling endosome. To examine transferrin uptake, transfected HeLa cells expressing OPTN and UBQLN2 were incubated with Alexa 594-conjugated transferrin. As shown in Supplementary Material, Figure S7C , labeled transferrin was largely distributed in OPTN+/UBQLN2+ vesicles after 15 min of incubation, suggesting that at least one role for these vesicles involves endosomal trafficking.
Rab11-dependent vesicular transport from recycling endosomes contributes to and regulates starvation-induced autophagy (10, 25) . In our study, immunocytochemistry analysis revealed that OPTN+/UBQLN2+ vesicles are positive for p62, LC3, APG9L1 and ATG16, a key molecule in the autophagic clearance of ubiquitinated proteins (Fig. 5A-C) .
Recent evidence (25) reveals that APG9L1 and ATG16 are mediators between the endosome and autophagosome. As show in Supplementary Material, Figure S8 , both APG9L1 and ATG16 are clearly localized in OPTN vesicles. We also found that OPTN+/UBQLN2+ vesicles co-localize in part with endogenous ULK1, which is present on early autophagosomes, and that the vesicles substantially co-localize with ULK1 (Fig. 5D) after amino acid starvation. Furthermore, in ATG5 (-/-) MEFs, both the size and number of vesicles formed by overexpressed OPTN are increased compared with ATG5 (+/+) MEFs (Fig. 5E) . Of ∼100 cells transfected in 4 independent experiments, the number of ATG5 (-/-) MEFs containing large OPTN vesicle (diameter, >1 μm) [mean ± standard deviation; 30.1 ± 7.8% (P < 0.03 versus ATG5 (+/+))] was significantly higher than that of ATG5 (+/+) MEFs (mean ± standard deviation; 20.6 ± 6.0%). Therefore, these findings indicate that these vesicles are linked with the autophagic system.
Recent reports (23, 24) and our results ( Fig. 6A and B) demonstrate that the ALS-linked E478G mutation in OPTN disrupts vesicle formation, suggesting that the vesicles play a role in the pathogenesis of ALS. To clarify the relevance of ALS-linked mutations in UBQLN2 and OPTN vesicles, we examined the distribution of mutant UBQLN2 (IVm) in N2a cells overexpressing OPTN. Co-localization of mutant UBQLN2 in OPTN vesicles was minimal, and mutant UBQLN2-IBs and OPTN vesicles were distinct ( Fig. 6C and D) . Because ΔPXX does not affect localization to OPTN vesicles (Supplementary Material, Fig. S5A ), the dominant effect of ALS-linked UBQLN2 mutations is to impede localization to OPTN vesicles, whereas loss of function of the PXX repeat region does not. Collectively, our results indicate that ALS-linked mutations in both OPTN and UBQLN2 affect vesicle formation.
Mutant UBQLN2 affects the regulation of progranulin levels
UBQLN is a multi-functional protein that regulates both UPS and autophagy (3) (4) (5) , and current studies revealed that UBQLN also functions as a chaperone to stabilize a number of proteasome substrates (5, (7) (8) (9) . In particular, recent evidence shows that UBQLN is a molecular chaperone for amyloid precursor protein, a secretory protein involved in endosomal trafficking (5, 8) . We therefore examined whether UBQLN2 or its IVm mutant affects the level of the pleiotropic growth factor progranulin to cause FTD with accumulation of TDP-43 (26), and in some cases, development of ALS (27) . We confirmed that progranulin is secreted via endosomal trafficking and that some intracellular progranulin localizes in OPTN+/UBQLN2+ vesicles (Fig. 7A ). Although changes in the level of intracellular progranulin were not significant in cells transiently expressing progranulin-tagged V5, the level of progranulin secretion by cells overexpressing wild-type UBQLN2 was significantly higher than that in cells transfected with an empty vector (EV) (Fig. 7B ), but not in IVm-expressing cells. To clarify the mechanistic basis of this observation, we treated UBQLN2/progranulin-coexpressing cells with the proteasome and autophagy inhibitors 3-methyladenine (3-MA) and MG132. Treatment with 3-MA led to upregulation of progranulin secretion by cells transfected with EV and IVm but not in wildtype UBQLN2-expressing cells, indicating that UBQLN2 is a potent regulator of progranulin, possible via circumvention of autophagic degradation (Fig. 7C) . To confirm this finding, we examined the effect of mutation number in cells stably expressing progranulin. As shown in Figure 8 , the number of ALS-linked mutations had an additive effect in reducing this upregulation of progranulin secretion. Collectively, these results suggest that UBQLN2 plays a role in increasing progranulin levels, possibly via autophagy, and that ALS-linked mutations disturb these functions.
Discussion
Our results provide several important insights into the molecular pathogenesis of UBQLN2-linked ALS/FTD. First, ALS-linked mutations in UBQLN2 additively enhance aberrant aggregation, resulting in formation of IBs in predominantly neuronal cells (Figs. 1 and 2) . Notably, deletion of the PXX repeat region, in which ALS-linked mutations are clustered (1), does not promote aggregation and IB formation, indicating that while substitution mutations for proline in this region are unlikely to disrupt the intrinsic role of the PXX repeat region, they do have toxic effects, possibly including interference with proper protein folding or self-assembly. Mutant UBQLN2-IBs, which have unique characteristics and appear to be distinct from aggresomes (Fig. 3) , are ubiquitin-and p62-positive but TDP-43-and FUS-negative. Pathological observations in UBQLN2-linked ALS/FTD indicate that the unique UBQLN2 inclusions in the hippocampus are positive for ubiquitin and p62 but are negative for FUS and mostly TDP43-independent (1). Therefore, the mutant UBQLN2-IBs in our study seem to be a feature of UBQLN2 inclusions in the hippocampus in UBQLN2-linked ALS/FTD.
We found that two ALS-linked molecules, OPTN and UBQLN2, localize to the same cellular compartment, Rab11-positive endosomal vesicles (Fig. 4) , suggesting that these proteins are involved in the same pathological processes in motor-neuron degeneration. A recent study revealed that Rab11-dependent vesicular transport from recycling endosomes contributes to and regulates autophagy upon amino acid starvation (10) . As expected, we found that OPTN+/UBQLN2+ vesicles not only show the characteristics of recycling endosomes but are also positive for the key autophagy-regulating molecules p62, LC3, mAPG9L1 and ATG16, and the autophagy initiator ULK1 (Fig. 5) , suggesting that these vesicles are involved in protein homeostasis. Interestingly, ALS-linked mutations in both OPTN and UBQLN2 interfered with the formation of and distribution of the protein to OPTN +/UBQLN2+ vesicles, respectively (Fig. 6 ). This suggests that OPTN+/UBQLN2+ vesicles contribute to protein homeostasis in the endosomal system via autophagy, and it is possible that disrupting the function of OPTN+/UBQLN2+ vesicles leads to the development of ALS/FTD (Fig. 9) .
UBQLN is a multi-functional protein that is linked to the ERAD pathway, by which misfolded proteins are translocated from the ER to the cytoplasm by the UPS (3) (4) (5) . Apart from this function, recent evidence also reveals that UBQLN is a molecular chaperone involved in the trafficking and degradation of amyloid precursor protein (5, 8) . In this study, we also found that UBQLN2 has a novel function as a potent regulator of the levels of progranulin via circumvention of autophagic degradation in endosomal trafficking. Because haploinsufficiency or deficiency of progranulin causes FTD (23, 26) , our finding indicates that inadequate levels of progranulin may also contribute to the pathogenesis of UBQLN2-linked ALS/FTD.
When interpreting the results of the present study, an important point should be kept in mind. Although the level of aggregated mutant UBQLN2 was significantly elevated in cells expressing the single-mutation (P497H) form (Fig. 1B) , a significant increase in IB formation and dysregulation of the progranulin level were observed in cells expressing multiple-mutation (IIIm and IVm) forms of UBQLN2 but not in cells expressing single-mutation (P497H) UBQLN2. Multiple mutations associated with neurodegenerative diseases such as FUS-related ALS and tauopathy enhance the toxic phenotype and facilitate the emergence of pathological characteristics (21, 28, 29) . The graphs shown in Figures 2B and 8 demonstrate the additive effects of UBQLN2 mutations, suggesting that multiple mutations in UBQLN2 not only reflect but also enhance the subtle phenotype associated with the single mutation. However, more detailed examinations using knock-in/-down or patient-derived cells [such as induced pluripotent stem (iPS) or neuronal (iN) cells] are needed to define the toxic phenotype associated with the single mutation.
Thus far, the evidence indicates that at a minimum, ALSlinked mutations in UBQLN2 affect multiple pathways of neurodegeneration, the UPS, autophagy and chaperone activity. Although further investigations are required to elucidate the precise pathogenesis of UBQLN2-and OPTN-linked ALS/FTD, our study provides novel insights that suggest OPTN and UBQLN2 may function in common pathological processes. This suggests a novel ALS/FTD disease spectrum in which protein homeostasis in the endosomal system could be a novel therapeutic target for ALS/FTD treatments.
Materials and Methods
Cell culture
HeLa, NSC-34, 293T, COS, N2a and ATG5-knockout mouse embryonic fibroblast (ATG5(-/-) MEF) (30) cells were maintained as described previously (20) (21) (22) 31 ) in Dulbecco's modified Eagle's medium (Gibco, Grand Island, NY) containing 10% fetal bovine serum. Transfection was performed using Lipofectamine 2000 (Life Technologies Corporation, Carlsbad, CA, USA) according to the manufacturer's instructions. Starvation medium consisted of EBSS, which contained 0.25 mg/ml of leupeptin (Sigma) where indicated. Primary neuronal cultures were prepared from the cortices of mouse embryos as described previously (32) . Briefly, cortices of ICR mice embryos at embryonic day 14 (E14) were dissociated into single cells in 10 U/mL papain solution (Wako Pure Chemical Industries, Ltd, Osaka, Japan) and resuspended in fresh nerve culture medium. Nerve culture medium were prepared from Neurobasal medium (Invitrogen, Carlsbad, CA, USA) with 2% B-27 supplement (Invitrogen) and 1% penicillin/streptomycin (Invitrogen). All animal experiments were performed in accordance with the Institutional Guidelines on Animal Experimentation at Keio University and approved by the Keio University Institutional Animal Care and Use Committee.
cDNA and plasmids UBQLN2 cDNA was cloned by PCR amplification of human UBQLN2 cDNA isolated from a HeLa cell cDNA pool using the primers 5′ ATTACGATGGCTGGGAGCCCA 3′ and 5′ GGCTGAGAAT GGCGAGAGCA 3′. The amplified cDNA was subcloned into pCS2 (+)MT. Deletion mutants and site-directed mutations in UBQLN2 were generated using a KOD-Plus-site-directed mutagenesis kit (Toyobo, Japan).
Wild-type, E50K, HA-OPTN (24), GFP-Rab11 (Addgene # 12674) (33), mRFP-Rab5 (Addgene # 14437) (34), EGFP-Rab7, mAPG9L1-Flag, 
Antibodies and reagents
Immunoblot analysis and filter retardation assay
After transfection for 48 h, cells were sonicated briefly in lysis buffer [50 m Tris-HCl, pH 7.4, 150 m NaCl, 0.5% Nonidet P-40, 0.5% sodium deoxycholate, 0.25% SDS, 5 m EDTA and protease inhibitor mixture (Sigma)]. Proteins were separated using reducing SDS-PAGE and then transferred onto a polyvinylidene difluoride membrane (Millipore). The membrane was incubated with primary antibody followed by horseradish peroxidase-conjugated secondary antibody. Enhanced chemiluminescence reagents were used according to the manufacturer's instructions (PerkinElmer Life Sciences). For filter retardation assays, samples were filtered through 0.2-μm cellulose acetate membrane (Sartorius Stedim Biotech, NY) filters using a slot blot apparatus (BioRad), as described previously (11) . The membrane was incubated with primary antibody followed by horseradish peroxidaseconjugated secondary antibody.
Statistical analysis
A statistical analysis of the data was performed using the Student's t-test or one-way ANOVA with Fisher's protected least squares difference test using the Statview 5.0 system (Statview, Berkley, CA, USA) or JMP 8 (SAS Institute, Inc., Cary, NC, USA).
